4-(6-nitrobenzo[d]thiazol-2-yl)benzenamine | 488722-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 4-(6-nitrobenzo[d]thiazol-2-yl)benzenamine
• 英文别名: 2-(4'-aminophenyl)-6-nitrobenzothiazole；4-(6-nitro-1,3-benzothiazol-2-yl)aniline
• CAS: 488722-59-4
• 化学式: C₁₃H₉N₃O₂S
• 分子量: 271.299
• InChiKey: ZMNKBEFBMDEOKB-UHFFFAOYSA-N

物化性质

• 沸点：
  505.2±56.0 °C(Predicted)
• 密度：
  1.461±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氯-6-硝基苯并噻唑 、 4-氨基苯硼酸频哪醇酯 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.1h， 生成 4-(6-nitrobenzo[d]thiazol-2-yl)benzenamine
  参考文献：
  名称：

  Hybrid Compounds And Methods Of Making And Using The Same

  摘要：

  本公开提供化合物或其药学上可接受的盐，用于抑制微生物的生长；治疗患有微生物感染、疟疾、粘膜炎、眼部感染、耳部感染、癌症或分枝杆菌感染的哺乳动物；杀灭或抑制疟原虫的生长；抑制分枝杆菌的生长；调节哺乳动物的免疫反应；或对抗非分馏肝素、低分子量肝素或肝素/低分子量肝素衍生物。

  公开号：

  US20140171438A1

文献信息

• Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies
  申请人：Klunk William E.

  公开号：US20080219931A1

  公开（公告）日：2008-09-11

  The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.

  目前用于确定淀粉样变性治疗疗效的方法包括向需要治疗的患者给予式（I）或式（II）或结构1-45的化合物，并对患者进行成像。在成像后，向该患者至少给予一种抗淀粉样蛋白药物。然后，向患者有效剂量的式（I）或式（II）或结构1-45的化合物，并再次对患者进行成像。最后，比较抗淀粉样蛋白药物治疗前患者的淀粉样沉积基线水平和治疗后患者的淀粉样沉积水平。
• Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition
  申请人：Klunk William E.

  公开号：US20080286202A1

  公开（公告）日：2008-11-20

  A method of identifying a patient as prodromal to a disease associated with amyloid deposition by imaging techniques is provided. In addition, a method of identifying amyloid deposition diseases in patients who present with a dementing disorder of questionable etiology by imaging techniques is provided. The methods discloses substances which are used for imaging and generating data which can be used to determine progress of an asymptomatic patient to a disease associated with amyloid deposition, or to identify amyloid deposition diseases in patients who present with a dementing disorder of questionable etiology.

  提供了一种通过成像技术识别患者是否为与淀粉样沉积相关的疾病的Prodromal的方法。此外，还提供了一种通过成像技术识别患有疑似病因的痴呆症患者中的淀粉样沉积疾病的方法。该方法揭示了用于成像和生成数据的物质，这些数据可用于确定无症状患者向与淀粉样沉积相关的疾病的进展，或者识别患有疑似病因的痴呆症患者中的淀粉样沉积疾病。
• THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION
  申请人：KLUNK E. William

  公开号：US20080021077A1

  公开（公告）日：2008-01-24

  This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

  本发明涉及一种新型噻吩啉衍生物，其使用方法包括在体内成像患有神经纤维斑块的患者，以及包含该噻吩啉衍生物的制药组合物和合成该化合物的方法。该化合物在诊断和治疗神经纤维斑块积累普遍存在的疾病患者中具有特殊用途。这些疾病状态或病症包括但不限于阿尔茨海默病、家族性阿尔茨海默病、唐氏综合症和载脂蛋白E4等位基因纯合体。
• AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES
  申请人：KLUNK William E.

  公开号：US20120177572A1

  公开（公告）日：2012-07-12

  The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.

  目前评估淀粉样变性疗法疗效的方法包括向需要治疗的患者施用式(I)或式(II)或结构1-45的化合物，并对患者进行成像。成像后，至少给该患者施用一种抗淀粉样物质。然后，向患者施用有效量的式(I)或式(II)或结构1-45的化合物，并再次对患者进行成像。最后，将抗淀粉样物质治疗前患者的淀粉样沉积基线水平与抗淀粉样物质治疗后患者的淀粉样沉积水平进行比较。
• THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER`S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION
  申请人：Klunk William E.

  公开号：US20130236394A1

  公开（公告）日：2013-09-12

  This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

  本发明涉及一种新的噻吩素衍生物，使用该衍生物的方法，例如在患有神经纤维结节的患者的体内成像，包含该噻吩素衍生物的制药组合物以及合成该化合物的方法。该化合物在诊断和治疗患有神经纤维结节积累的疾病的患者中具有特殊用途。这些疾病状态或疾病包括但不限于阿尔茨海默病，家族性阿尔茨海默病，唐氏综合症和载脂蛋白E4等位基因的纯合子。